682 results about "Brain damage" patented technology

Provided are thiadiazolidine compounds of formula I

wherein R₁ is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.

During childbirth, trauma to the infant can readily arise, ultimately resulting in fetal hypoxia, academia, and brain damage. Such unfavorable conditions can be best ascertained by real-time monitoring of the fetus' blood-oxygen level, heart rate monitoring, EKG and EEG waveforms. This invention describes a system of monitoring devices to implement such goals and maximize the potential welfare of the fetus. It furthermore allows the formation of a reference database that can correlate intrapartum events from prior births. The embodiments utilize a small-diameter sensor inserted into the birth canal through a tubular insertion rod. Through wire, fiber optics, and or using a radio frequency link, fetal monitor data can be analyzed, compared to existing data base, and or transmitted via internet. This patent details various apparatuses that allow important life-sign parameters of a fetus to be continuously monitored.

A method of enhancing the regeneration of injured nerves has the step of administering an effective exposure of pressure pulses or acoustic shock waves in a pulse or wave pattern to the zone of injury of the nerve during the regeneration process. The inventive method may include enhancing the stimulation of neuronal cell growth or regeneration by administering an effective exposure of pressure pulses or acoustic shock waves in a pulse or wave pattern to stimulate neuronal cell growth or regeneration, wherein the administering of the treatment is applied to a patient who has a pathological condition where neuronal repair can be facilitated including peripheral nerve damage caused by injury or disease such as diabetes, brain damage associated with stroke, and for the treatment of neurological disorders related to neurodegeneration, including Parkinson's disease, Alzheimer's disease and amyotrophic lateral, sclerosis multiple sclerosis and disseminated sclerosis. The treatment is ideally suited for neural regeneration after a degenerative condition due to any neurological infections or any other pathological condition.

Brain-Machine Interface (BMI) systems or movement-assist systems may be utilized to aid users with paraplegia or tetraplegia in ambulation or other movement or in rehabilitation of motor function after brain injury or neurological disease, such as stroke, Parkinson's disease or cerebral palsy. The BMI may translate one or more neural signals into a movement type, a discrete movement or gesture or a series of movements, performed by an actuator. System and methods of decoding a locomotion-impaired and/or an upper-arm impaired subject's intent with the BMI may utilize non-invasive methods to provide the subject the ability to make the desired motion using an actuator or command a virtual avatar.

The invention relates to a levo-oxiracetam slow-release tablet mainly prepared from levo-oxiracetam, which is prepared from the following raw and auxiliary materials in parts by weight: 0.8-1.2 parts of slow-release framework material, 0.06-0.12 part of flow aid, 0.02-0.05 part of lubricant, 0.02-0.05 part of antisticking agent and 1-1.5 parts of adhesive. The levo-oxiracetam slow-release tablet is used for treating brain injury, and neural afunction and disturbance of memory and intelligence caused by brain injury, and has a smooth surface; the detection proves that the release behavior of the main drug levo-oxiracetam satisfies the requirements for the slow-release tablet; and the main drug levo-oxiracetam is slowly released, so the levo-oxiracetam slow-release tablet can be taken less frequently than the traditional preparation. The main drug levo-oxiracetam in the levo-oxiracetam slow-release tablet is slowly released, and can provide steady and enduring effective blood concentration, thereby avoiding or reducing the phenomena of peaks and troughs of blood concentration, and being beneficial to enhancing the medicine application safety and reducing the untoward reaction of the medicine.

Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I) and (III): where R¹, R², R³, R^3′, R₄, R^6a, R^6a, R^11a, and R^11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, insomnia, anxiety, depression, traumatic brain injury (TBI), stress, and epilepsy.

A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, in a sample of body fluid taken from the subject, wherein the polypeptide is one for which the level is either increased or decreased in cerebrospinal fluid from deceased patients compared to cerebrospinal fluid from healthy donors.

A system for reducing the damaging effects of radiant energy, blast, or concussive events includes applying pressure to at least one jugular vein to reduce the egress of blood from the cranial cavity during or before the incidence of the imparting event. Reducing blood outflow from the cranial cavity increases intracranial volume and/or pressure of the cerebrospinal fluid to reduce the risk of traumatic brain injury and injuries to the spinal column. Reducing blood outflow further increases the intracranial pressure and volume, and thereby increases the pressure and volume of the cochlear fluid, the vitreous humor and the cerebrospinal fluid to thereby reduce the risk of injury to the inner ear, internal structure of the eye and of the spinal column. In addition, increasing intracranial pressure and volume reduces the likelihood of brain injury and any associated loss of olfactory function

Apparatuses and methods for the cooling of the cranial and extracranial portions of a patient in need thereof. The apparatuses and methods of the present invention preferably employ a head cooling apparatus which includes a watertight shroud for the head and which needs no refrigeration. In certain preferred embodiments, the apparatuses of the present invention are collapsible and possess a reduced profile. In some presently preferred embodiments, the present invention includes a hammock that supports the head. In some embodiments, the present invention includes a shroud that lies behind the head with optional portions that may be drawn over the patient's neck and cranial area. The apparatuses and methods of the present invention also provide an improved mechanism for cooling the cranial and extracranial areas through the use of a novel distribution of endothermic solids (e.g. ammonium nitrate). The present invention provides a novel distribution of ammonium nitrate pellets that preferably includes multiple populations solid ammonium nitrate, preferably including small diameter (e.g., powdered) and larger diameter (e.g., 7 millimeter) ammonium nitrate to allow water initially to be cooled very quickly, thereby facilitating the rapid cooling of the cranial and extracranial areas, while at the same time producing extended hypothermia.

There is disclosed headwear comprising an endothermic reactor and a trigger to initiate an endothermic reaction in the reactor whilst being worn on a wearer's head. Such may preferentially be utilised in or in conjunction with a motorcycle safety helmet or similar crash protection device. The headwear is intended to prevent or delay the onset of brain damage as a result of serious trauma or head injury.

Disclosed is a method for improving cognitive function or for improving coordination of function across a patient's cortical regions. The method includes applying electrical stimulation to at least a portion of the patient's subcortical structures involved in the generation and control of generalized efference copy signals. Internally generated movement of the patient is then detected and, in response to such internally generated movement, application of electrical stimulation is controlled. The method of the present invention has a number of benefits, including increasing flexibility in identifying targets for stimulation, improving the probability of successfully treating brain injury, and permitting patient biofeedback and self-regulation.

The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NCca-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and/or TRPM4 antagonists that inhibit the NCca-ATP channel may be employed in the combination. The combination therapy also employs one or more of a non-selective cation channel blocker and/or an antagonist of VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy includes the prevention, diminution, and/or treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury, for example. In other embodiments, there are methods and compositions directed to antagonists of TRPM4, including at least for therapeutic treatment of traumatic brain injury, cerebral ischemia, central nervous system (CNS) damage, peripheral nervous system (PNS) damage, cerebral hypoxia, or edema, for example.

The invention relates to methods of obtaining an expanded population of mammalian ex vivo cells and/or for treating a mammalian subject by (a) administering to a subject an effective amount of an agent that confers a growth disadvantage to at least a subset of endogenous cells at the site of engraftment; (b) administering to the subject an effective amount of a mitogenic stimulus for the ex vivo cells; and (c) administering the ex vivo cells to the subject, wherein the ex vivo cells engraft at the site and proliferate to a greater extent than the subset of endogenous cells, to repopulate at least a portion of the engraftment site with the ex vivo cells. The repopulated cells can be harvested for further use or be left at the engraftment site of a subject to be treated. The invention also provides methods of treating brain injury in a subject by engrafting ex vivo cells at the site of injury.

Processes and materials are provided for the detection, diagnosis, or determination of the severity of a neurological injury or condition, including traumatic brain injury, multiple-organ injury, stroke, Alzeimer's disease, Pakinson disease and Chronic Traumatic Encephalopathy (CTE). The processes and materials include biomarkers detected or measured in a biological sample such as whole blood, serum, plasma, or CSF. Such biomarkers include Tau and GFAP proteins, their proteolytic breakdown products, brain specific or enriched micro-RNA, and brain specific or enriched protein directed autoantibodies. The processes and materials are operable to detect the presence of absence of acute, subacute or chronic brain injuries and predict outcome for the brain injury.

The present invention provides an electrode designed for implantation into the central nervous system (CNS) of a mammal, wherein said electrode is substantially coated with interleukin-1 receptor antagonist (IL-1ra) or a coating composition comprising it, and the IL-1ra actively inhibits scarring on or around the surface of the electrode when implanted into the CNS. The electrode of the invention may be used for brain recording and/or stimulation, and can thus be used for treatment of a brain dysfunction, a brain disease or disorder, or a brain injury, as well as for brain computer interface, brain machine interface, or electrotherapy.

Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, and status epilepticus.

A non-invasive method for measuring intracranial pressure (ICP) is provided. A numerical model such as finite element model is developed in order to calculate the ICP, strain or stress for patients who suffers from hematoma, edema or tumor. The method can further provide local maximum principle strain that can provide information about possible subsequent brain injury, such as diffuse axonal injury, in sensitive region of the brain. Based on computer tomography or magnetic resonance images an individual diagnosis and treatment plan can be formed for each patient.

Rapid and accurate in-vivo assessment of cerebral white matter injury particularly for pre-term infants, for timely treatment and/or prediction of outcomes has been very limited. This invention exploits the discovery that reduced high-frequency EEG intensity, particularly as shown by the upper spectral edge frequency, is a good indicator of cerebral white matter neural injury and is well correlated with MRI results. With more experience of clinical cases, a set of simple rules such as "if the spectral edge value is below 8 Hz there is a high likelihood of injury" may be validated, yet the EEG technology involved is largely invisible to the user. In the invention, EEG signals are processed by software to obtain, store, and graphically display bilaterally collected EEG spectral edge and intensity values over from hours to weeks. Rejection of corrupted signals by filtering and gating means is responsive to incoming signal characteristics, to additional inputs such as motion sensors or impedance tests, and to patient data (gestational age in particular). The invention includes the software and methods of use.

The present invention relates to an apparatus for the treatment of a brain affection, which comprises at least one implantable generator (4) made of non-ferromagnetic material comprising a casing (7), an ultrasound generating treating device (11) positioned into said casing to induce brain affection treatment by emission of ultrasound waves, and means for fastening the implantable casing into the skull. The apparatus further comprises a power controller (PwC) to supply electricity to the treating device of the implantable generator and to set and control its working parameters, and connecting means (6) to connect the power controller and the treating device of the implantable generator. A method for treating a brain affection with such an apparatus is also disclosed.